# Acetate Metabolism in Thyroid Cancer Progression

**Authors:** Enke Baldini, Silvia Cardarelli, Eleonora Lori, Poupak Fallahi, Camilla Virili, Marco Centanni, Vito D’Andrea, Alessandro Antonelli, Salvatore Sorrenti, Salvatore Ulisse

PMC · DOI: 10.3390/ijms27042013 · International Journal of Molecular Sciences · 2026-02-20

## TL;DR

This study explores how thyroid cancer cells use acetate for energy and finds that certain genes related to acetate metabolism are less active in cancerous tissues compared to normal ones.

## Contribution

The study identifies specific genes in acetate metabolism that are dysregulated in thyroid cancer, particularly in aggressive forms.

## Key findings

- Genes like ACSS1, ACSS2, ACACB, PDHA1, SLC16A3, and SLC16A7 are downregulated in papillary thyroid cancers compared to normal tissues.
- BRAF-mutated tumors and aggressive variants show even lower expression of these genes.
- ACSS2 is upregulated in anaplastic thyroid carcinomas, indicating metabolic adaptation in aggressive cancers.

## Abstract

In recent years, several studies have highlighted the ability of malignant cells to use acetate as an alternative energy and biosynthetic source to glucose. In this context, the present study aimed at characterizing the expression profile of genes involved in acetate metabolism in thyroid carcinomas. To this end, we analyzed molecular and clinical data from 496 papillary thyroid cancers (PTCs) and 59 normal thyroid tissues from The Cancer Genome Atlas (TGCA). In addition, we examined 57 PTCs and matched normal tissues, and six anaplastic thyroid carcinomas (ATCs) collected in our institutions, using real time RT-PCR. The results show a downregulation of ACSS1, ACSS2, ACACB, PDHA1, SLC16A3 and SLC16A7 genes in PTCs compared with normal tissues, some of which were significantly lower in BRAF-mutated tumors, the more aggressive tall cell variant, and larger and/or metastatic PTCs. Overall, these findings point to a reduction in mitochondrial oxidative pathways that was more evident in advanced or aggressive disease forms. In ATCs, ACSS2 was the only upregulated gene, suggesting further tumor adaptation to the metabolic stress of rapidly growing cancers. In conclusion, our study demonstrates a dysregulated expression pattern of multiple genes involved in acetate metabolism, which could be exploited for the development of new therapeutic strategies.

## Linked entities

- **Genes:** ACSS1 (acyl-CoA synthetase short chain family member 1) [NCBI Gene 84532], ACSS2 (acyl-CoA synthetase short chain family member 2) [NCBI Gene 55902], ACACB (acetyl-CoA carboxylase beta) [NCBI Gene 32], PDHA1 (pyruvate dehydrogenase E1 subunit alpha 1) [NCBI Gene 5160], SLC16A3 (solute carrier family 16 member 3) [NCBI Gene 9123], SLC16A7 (solute carrier family 16 member 7) [NCBI Gene 9194], BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673]
- **Chemicals:** acetate (PubChem CID 175)
- **Diseases:** thyroid cancer (MONDO:0002108), papillary thyroid cancer (MONDO:0005075), anaplastic thyroid carcinoma (MONDO:0006468)

## Full-text entities

- **Genes:** PDP1 (pyruvate dehydrogenase phosphatase catalytic subunit 1) [NCBI Gene 54704] {aka PDH, PDP, PDPC, PDPC 1, PPM2A, PPM2C}, TSHR (thyroid stimulating hormone receptor) [NCBI Gene 7253] {aka CHNG1, LGR3, hTSHR-I}, NKX2-1 (NK2 homeobox 1) [NCBI Gene 7080] {aka BCH, BHC, NK-2, NKX2.1, NKX2A, NMTC1}, ACLY (ATP citrate lyase) [NCBI Gene 47] {aka ACL, ATPCL, CLATP}, ACACA (acetyl-CoA carboxylase alpha) [NCBI Gene 31] {aka ACAC, ACACAD, ACACalpha, ACC, ACC1, ACCA}, TENM1 (teneurin transmembrane protein 1) [NCBI Gene 10178] {aka ODZ1, ODZ3, TEN-M1, TEN1, TNM, TNM1}, SLC16A1 (solute carrier family 16 member 1) [NCBI Gene 6566] {aka HHF7, MCT, MCT1, MCT1D}, SLC16A4 (solute carrier family 16 member 4) [NCBI Gene 9122] {aka MCT4, MCT5}, ACSS1 (acyl-CoA synthetase short chain family member 1) [NCBI Gene 84532] {aka ACAS2L, ACECS1, AceCS2L}, BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673] {aka B-RAF1, B-raf, BRAF-1, BRAF1, NS7, RAFB1}, SLC26A4 (solute carrier family 26 member 4) [NCBI Gene 5172] {aka DFNB4, EVA, PDS, TDH2B}, DUOX1 (dual oxidase 1) [NCBI Gene 53905] {aka LNOX1, NOXEF1, THOX1}, TPO (thyroid peroxidase) [NCBI Gene 7173] {aka MSA, TDH2A, TPX}, THRA (thyroid hormone receptor alpha) [NCBI Gene 7067] {aka AR7, CHNG6, EAR7, ERB-T-1, ERBA, ERBA1}, GLIS3 (GLIS family zinc finger 3) [NCBI Gene 169792] {aka NDH, ZNF515}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, PDHA1 (pyruvate dehydrogenase E1 subunit alpha 1) [NCBI Gene 5160] {aka E1alpha, PDHA, PDHAD, PDHCE1A, PHE1A}, SLC16A3 (solute carrier family 16 member 3) [NCBI Gene 9123] {aka MCT 3, MCT 4, MCT-3, MCT-4, MCT3, MCT4}, ACSS2 (acyl-CoA synthetase short chain family member 2) [NCBI Gene 55902] {aka ACAS2, ACECS, ACS, ACSA, AceCS1, dJ1161H23.1}, SLC16A7 (solute carrier family 16 member 7) [NCBI Gene 9194] {aka MCT2}, THRB (thyroid hormone receptor beta) [NCBI Gene 7068] {aka C-ERBA-2, C-ERBA-BETA, ERBA2, GRTH, NR1A2, PRTH}, DIO1 (iodothyronine deiodinase 1) [NCBI Gene 1733] {aka 5DI, THMA2, TXDI1}, ACACB (acetyl-CoA carboxylase beta) [NCBI Gene 32] {aka ACACbeta, ACC-beta, ACC2, ACCB, ACCbeta, HACC275}, Acaca (acetyl-Coenzyme A carboxylase alpha) [NCBI Gene 107476] {aka A530025K05Rik, Acac, Acc1, Gm738}, DIO2 (iodothyronine deiodinase 2) [NCBI Gene 1734] {aka 5DII, D2, DIOII, SELENOY, SelY, TXDI2}, DUOX2 (dual oxidase 2) [NCBI Gene 50506] {aka LNOX2, NOXEF2, P138-TOX, TDH6, THOX2}, SLC5A5 (solute carrier family 5 member 5) [NCBI Gene 6528] {aka NIS, TDH1}, FOXE1 (forkhead box E1) [NCBI Gene 2304] {aka BAMLAZ, FKHL15, FOXE2, HFKH4, HFKL5, NMTC4}, CPT1A (carnitine palmitoyltransferase 1A) [NCBI Gene 1374] {aka CPT I, CPT1, CPT1-L, CPTI-L, L-CPT1}, FASN (fatty acid synthase) [NCBI Gene 2194] {aka FAS, OA-519, SDR27X1}, PAX8 (paired box 8) [NCBI Gene 7849] {aka PAX-8}, SLC5A8 (solute carrier family 5 member 8) [NCBI Gene 160728] {aka AIT, SMCT, SMCT1}
- **Diseases:** hypoxia (MESH:D000860), TC (OMIM:275350), glioblastoma (MESH:D005909), thyroid function (MESH:D013966), tumorigenesis (MESH:D063646), ovarian and renal cancers (MESH:D010051), PTC (MESH:D000077273), hypoxic (MESH:D002534), BC (MESH:D001943), Lymph node metastases (MESH:D008207), undifferentiated tumors (MESH:D002277), endocrine malignancies (MESH:D004700), Cancer (MESH:D009369), ATC (MESH:D001260), ATCs (MESH:D065646), Epithelial thyroid cancers (MESH:D013964), nodal disease (MESH:D004194), injury to (MESH:D014947)
- **Chemicals:** FADH2 (MESH:C058805), glucose (MESH:D005947), NADH (MESH:D009243), Acetate (MESH:D000085), Malonyl-CoA (MESH:D008316), nucleotides (MESH:D009711), lipid (MESH:D008055), Acetyl-CoA (MESH:D000105), steroids (MESH:D013256), glutamine (MESH:D005973), Citrate (MESH:D019343), ATP (MESH:D000255), FA (MESH:D005227), TCA (MESH:D014233), coenzyme A (MESH:D003065), nitrogen (MESH:D009584), radioiodine (MESH:C000614965), lactate (MESH:D019344), oxygen (MESH:D010100), fats (MESH:D005223), pyruvate (MESH:D019289), equivalents (-)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** BRAFV600E

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12940943/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12940943/full.md

## References

57 references — full list in the complete paper: https://tomesphere.com/paper/PMC12940943/full.md

---
Source: https://tomesphere.com/paper/PMC12940943